600812 Stock Overview
Operates as a chemical pharmaceutical company in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
North China Pharmaceutical Company.Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.52 |
| 52 Week High | CN¥6.66 |
| 52 Week Low | CN¥3.83 |
| Beta | 1.16 |
| 11 Month Change | -0.54% |
| 3 Month Change | 15.72% |
| 1 Year Change | -11.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600812 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.1% | -0.6% | -2.8% |
| 1Y | -12.0% | -8.7% | 2.0% |
Return vs Industry: 600812 underperformed the CN Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 600812 underperformed the CN Market which returned 3.2% over the past year.
Price Volatility
| 600812 volatility | |
|---|---|
| 600812 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600812 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600812's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1953 | 10,159 | Xin Yan Liu | www.ncpc.com |
North China Pharmaceutical Company Ltd operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs; biotechnology drugs; cardiovascular cerebrovascular; immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs.
North China Pharmaceutical Company.Ltd Fundamentals Summary
| 600812 fundamental statistics | |
|---|---|
| Market cap | CN¥9.47b |
| Earnings (TTM) | CN¥79.38m |
| Revenue (TTM) | CN¥9.71b |
119.3x
P/E Ratio1.0x
P/S RatioIs 600812 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600812 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.71b |
| Cost of Revenue | CN¥6.74b |
| Gross Profit | CN¥2.97b |
| Other Expenses | CN¥2.89b |
| Earnings | CN¥79.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 0.046 |
| Gross Margin | 30.61% |
| Net Profit Margin | 0.82% |
| Debt/Equity Ratio | 172.4% |
How did 600812 perform over the long term?
See historical performance and comparison